131 |
Tyrosine kinase activation by intestinal bacteria : implications for ulcerative colitisHyde, Gillian Mary January 2000 (has links)
No description available.
|
132 |
Investigating the role of psychological flexibility and the use of an acceptance and commitment therapy based intervention in irritable bowel syndromeFerreira, Nuno Monteiro Da Rocha Bravo January 2011 (has links)
Irritable Bowel Syndrome (IBS) is a common chronic illness thought to be originated and maintained by a combination of physiological, psychological and social factors. IBS is known to be associated with a high psychosocial impact on patients’ lives. Acceptance and Commitment Therapy (ACT) is an emerging model of conceptualization and treatment that states that most suffering in chronic illness can be explained by a lack of psychological flexibility or acceptance to experience aversive bodily sensations, thoughts or emotions. ACT treatments target the increase of psychological flexibility as a key change for improvement in outcomes. Recent studies suggest that ACT could not only be an effective alternative treatment for IBS, as it might provide a valuable model of understanding of the relations between the different factors related to this condition and its outcomes. The first aim of the present research was to investigate the role of psychological flexibility in IBS, in particular, how acceptance relates to psychological, emotional and physical factors in this condition. The second aim was to investigate the effectiveness of an ACT based intervention in increasing psychological flexibility in IBS and thereby improving IBS Outcomes. These aims were addressed by conducting two related studies. In Study 1, a sample of 121 IBS patients attending a specialized gastroenterology clinic completed a series of self-report measures of psychological flexibility (acceptance), psychological factors known to be associated with IBS and IBS outcomes. Results indicated that higher levels of acceptance were generally associated with and predicted better levels of IBS biopsychosocial factors. Results also showed that acceptance mediated most of the relationships between IBS predictors and Outcomes. Also, psychometric analyses of a novel measure of IBS Acceptance (i.e. IBS Acceptance and Action Questionnaire) created for this study demonstrated that it had good reliability and validity. In Study 2, fifty six IBS patients enrolled in an intervention involving a one day ACT workshop and an ACT based self-help workbook. Thirty six participants provided follow-up data up to 6 months after the workshop. Results indicated that there were significant increases in acceptance and significant improvement in IBS outcomes between pre-treatment and follow-up. Further to that, analyses indicated that changes in IBS Outcomes occurred through changes in acceptance as hypothesized by the ACT model. These studies suggest that psychological flexibility processes are important in the understanding of IBS and that improvement in this condition may result from a more psychologically flexible stance to it. Although preliminary, these studies provide a basis for the further development and application of the ACT model of conceptualization and treatment in IBS.
|
133 |
The role of the IL23/IL17 pathway in inflammatory bowel diseaseGeremia, Alessandra January 2011 (has links)
The aetiology of IBD is unknown, but available evidence suggests that an aberrant immune response towards the commensal microbial flora is responsible for intestinal inflammation in genetically susceptible individuals. Studies from animal models of intestinal inflammation have greatly advanced our understanding of the immunological basis of IBD. However, translation of results from animal research into human studies is essential in order to improve treatment options and patient quality of life. In this thesis we present the successful introduction of translational studies on human tissue in our laboratory. In particular, we evaluated the role of the IL23/IL17 pathway in the human immune response and its role in IBD. IL23-driven inflammation has been primarily linked to its activity on Th-17 cells; however, work from our laboratory has identified a novel population of IL23-responsive ILC, which are responsible for innate colitis in mice. Here we have analyzed the role of IL23-responsive innate cells in IBD. Our results show increased expression of Th-17 signature genes amongst intestinal CD3- cells in patients with IBD. Furthermore, we observed a marked and selective increase in IL17 producing CD56- ILC in the inflamed intestine of patients with CD. ILC may contribute to intestinal inflammation through secretion of cytokines, such as IL17A and IL17F, and recruitment of other inflammatory cells, representing a novel tissue-specific target for the treatment of IBD. In addition, we present here our preliminary data on the characterization of human intestinal and systemic DC populations. In particular, we aimed to evaluate if in the context of the intestinal microenvironment DC develop specific regulatory features, as observed in murine CD103+ DC. We show that human intestinal DC populations exhibit specific regulatory properties, such as expression of genes associated with TGF-β and RA activity. Furthermore, CD103+ DC are present in the human gut and are characterized by tolerogenic markers. Remarkably, patients with IBD have reduced frequencies of intestinal CD103+ DC, which display a more pro-inflammatory phenotype. Alteration in DC subset composition and functional activity may result in a distort balance between immune effector and regulatory responses, promoting the development of intestinal inflammation.
|
134 |
Paediatric inflammatory bowel disease : bench to bedside and nationwide : a detailed analysis of Scottish children with IBDHenderson, Paul January 2013 (has links)
The inflammatory bowel diseases (IBDs) are a group of chronic conditions affecting the gastrointestinal tract, often presenting with non-specific clinical features such as abdominal pain, weight loss and diarrhoea. Approximately 25% of patients are diagnosed with IBD in childhood. For epidemiological studies, previously collected (1990-1995) and original (2003-2008) Scottish incidence data were used to determine national trends in newly diagnosed paediatric IBD (PIBD). A smaller, geographically defined, prospective 14-year cohort (1997- 2011) in South-East Scotland (SES) was used to assess regional trends in incidence, point prevalence, disease extent, medication use and PIBD surgery rates in 326 children. For the detailed analysis of the role of ICOSLG and CRP in Scottish children with PIBD, haplotype-tagging of both genes in 448 children (and their parents) registered on the Paediatric Inflammatory bowel disease Cohort and Treatment Study (PICTS) database was performed. Further clinical information from this database and previously gathered adult mRNA microarray data were also used to inform the analysis. For the faecal calprotectin (FC) case-control study, all PIBD patients diagnosed in SES between 01.01.05 and 31.12.10 (aged 1- 17yrs) with a FC performed during initial workup were identified; controls were matched non- IBD patients who had similarly undergone endoscopy with a referral FC level available. The systematic review and meta-analysis of FC case-control studies was performed with keywords relating to IBD and calprotectin in electronic resources from 1946 to May 2012. Inclusion criteria were studies that reported FC levels prior to the endoscopic investigation of IBD in children less than 18 years old. Laboratory work used newly derived HEK293 and HCT116 cell lines stably expressing wild-type NOD2 and the CD-associated NOD2 frameshift mutant, as well as utilising previously derived HEK293 and HCT116 cells stably expressing green fluorescent-labelled protein LC3 during the assessment of autophagy. Western blot, immunofluorescent microscopy and flow cytometry were used for analysis. There was a significant rise in PIBD incidence in Scotland since the early 1990s, with 260 new cases between 1990-1995 (4.45/100,000/year) and 436 in the 2003-2008 epoch (7.82/100,000/year) (p<0.001). A five-fold increase in Crohn's disease (CD) in the last 40 years was also demonstrated. SES was shown to have the highest recorded PIBD incidence rate in the UK for the six-year epoch from 2006-2011 (9.50/100,000/year) with a significant rise in ulcerative colitis (UC) to 2.67/100,000/year (p=0.010). Point prevalence rates for PIBD in SES had also risen significantly to 41.2/100,000 between the 2000-2005 and 2006-2011 epochs (p=0.016). With a follow up of 1577 patient years, the severe phenotype in children with PIBD was confirmed; 34% of children with CD presented with pan-enteric disease (44% at follow up), and 76% of children with UC had pancolonic disease at diagnosis (81% at follow up). 26% of patients required methotrexate and 18% were exposed to infliximab/adalimumab, with the time to first exposure of both significantly lower in children diagnosed between 2006-2011 (p=0.001 and p<0.001 respectively). A total of 70% of children were exposed to azathioprine and 20% underwent IBD-related surgery. Using a haplotype-tagging approach and transmission disequilibrium testing (TDT) in 230 PIBD case-parent trios there was significant overtransmission of the rs8126734-A single nucleotide polymorphism (SNP) in ICOSLG following correction (p=0.0467). In the CD TDT analysis the same SNP was overtransmitted (p=0.0084). The strongest susceptibility signal was evident across the two marker haplotype rs762421-A / rs8126734-G (p=0.0072), suggesting that the 3-prime untranslated region in ICOSLG may be targeted for deep sequencing. mRNA microarray data from adult patients showed downregulation of ICOSLG expression in the ascending colon (p=0.023) and upregulation in the descending colon (p=0.0351) in uninflamed biopsies from CD patients and non-IBD controls; no difference in gene expression was shown in UC patients. Using a similar approach, the A allele of two SNPs tagging CRP showed significant over-transmission to affected IBD patients after correction (rs1417938, p=0.006; rs1130864, p=0.015). The six-marker haplotype (ACACAC) showed significant distortion of transmission to affected individuals (p=8x10-4). CD and UC patients demonstrated differences in rs1205 genotype (p=0.0085) and CRP haplotype (p=0.0024), with the influence of the rs1205 SNP on response to anti-tumour necrosis factor-alpha therapy also shown (p=0.021). During the FC case-control study significantly elevated FC levels at diagnosis were demonstrated compared to controls (1265 μg/g vs 65 μg/g; p<0.001). FC also outperformed commonly used blood parameters (e.g. CRP, ESR, platelets), with an area under the curve of 0.93 (95% CI 0.89-0.97) and good sensitivity (0.93 [95% CI 0.86-0.98]) and specificity (0.74 [95% CI 0.64-0.82]) when values above 200μg/g were used. FC levels were not influenced by disease location in CD or UC. The systematic review and meta-analysis highlighted the often poor methodological quality of previous studies and concluded that across all studies FC had a pooled sensitivity of 0.98 (95% CI 0.95-1.00) and pooled specificity of 0.68 (95% CI 0.50-0.86) for PIBD at diagnosis. Characterisation of cells stably-expressing wild-type NOD2 or the CD-associated NOD2 frameshift mutation demonstrated increased cell proliferation compared to empty vector, and an accentuated apoptotic response to serum starvation. The NOD2 frameshift protein had a shorter half-life (at 11 hours) than the wild-type protein, with degradation of the NOD2 protein shown to be mediated through a proteasome-dependent pathway, possibly through lysine residues on the CARD domain. Following the establishment of a robust method of assessing autophagy in a cell culture system, experimental work showed that muramyl dipeptide-induced autophagy is unlikely to signal through the mammalian target of rapamycin, with the intermediate filament vimentin shown to be intimately involved in this pathway; the vimentin gene (Vim) was also shown to be a candidate susceptibility gene for CD. Using a panel of PIBD drugs azathioprine was shown to induce autophagy in a dose-dependent manner through an mTOR-dependent, ERK-independent pathway. It can be seen that with the increasing incidence and prevalence of PIBD in Scotland that a greater understanding of epidemiological trends, the role of genetic susceptibility, the optimal use of biomarkers and translational functional biology are all needed to understand further the aetiopathogenesis of PIBD. This future work will undoubtedly help to inform service design and the clinical care pathways utilised to provide the best care for children in addition to targeting pathways for potential drug development, with these measures helping to prepare for the increasing disease burden generated by PIBD.
|
135 |
Vliv bilirubinu na progresi nespecifických střevních zánětů. / Bilirubin influence on the progression of inflammatory bowel disease.Patková, Anna January 2014 (has links)
Charles University in Prague Faculty of Pharmacy in Hradec Králové Department of Biological and Medical Sciences Bilirubin influence on the progression of inflammatory bowel disease Diploma thesis Anna Patková Supervisor: doc. PharmDr. Petr Nachtigal, Ph.D. Background: Inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, are chronic inflammatory disorders of the gut caused by an interaction of genetic and environmental factors. It is thought that tissue damage is also partly caused by an oxidative stress. Heme oxygenase-1 and bilirubin are strong antioxidants and both of them provide an anti-inflammatory effect in various tissues. The aim of this diploma thesis was to detect changes of expression of HO-I in the large intestine of normobilirubinemic and hyperbilirubinemic rats after the induction of acute or chronic experimental colitis. Methods: We used Gunn rats with hereditary defect of UDP-glucuronyltransferase, which causes hyperbilirubinemia. The control group of animals was made up of heterozygous littermates of the Gunn rats, which have normal serum bilirubin levels. All animals were treated by dextran sulfate sodium in order to induce an experimental colitis. Rats were divided into two groups. Each of them contained hyperbilirubinemic and normobilirubinemic...
|
136 |
Histone acetylation and inflammatory mediators in inflammatory bowel diseaseTsaprouni, Loukia G. January 2003 (has links)
During cell activation the tightly compacted DNA is made available to DNA-binding proteins allowing the induction of gene transcription. In the resting cell, DNA is packaged into chromatin whose fundamental subunit is the nucleosome, composed of an octamer of four core histones (H) 3, 4, 2A and 2B. During the induction of gene transcription, modification of histones, by acetylation, methylation etc., results in unwinding of the DNA, permitting access of large DNAbinding proteins, such as RNA polymerase II, and subsequent induction of gene transcription. This investigation initially examined the effects of pro-inflammatory stimuli LPS and TNF-a on the production of IL-8 in a macrophage cell line (U937 cells) and in two T-cell lines (Jurkat and HUT-78 cells) as a marker of NF-KB-directed inflammatory gene expression. The ability of dexamethasone (Dex) and triamcinolone acetonide (TA) (synthetic glucocorticoid agonists) to suppress expression of the inflammatory cytokine IL-8 and to regulate histone acetylation was also investigated in these cells. LPS and TNF-a caused an increase in IL-8 expression, which was further enhanced by the histone deacetylases inhibitor trichostatin A (TSA), suggesting a role for histone acetylation in IL-8 production in these cells. Dex and TA, repressed LPS- and TNF-a -induced IL-8 expression in all three cell lines. This effect of both Dex and TA was attenuated by TSA in all cell lines studied, where the effect of TSA was greater in TA stimulated cells. Stimulation of all cell lines with LPS and TNF-a induced acetylation of H4 lysine residues (K5, 8, 12 and 16), the highest elevation of which was for K8 and K12. Also demonstrate is a K5 and K16 specificity of acetylation by glucocorticoids, apparent in all cell lines studied. Dex and, to a greater extent, TA suppressed LPS- and TNFa-induced K8 and K12 acetylation. TSA attenuated the inhibitory effect of the glucocorticoids for all three cell lines. An inCrease in HDAC activity with GCs was observed and ChiP assay showed these events occur on the native IL-8 promoter via histone acetylation. Further studies investigated whether there were any links between histone acetylation and the regulation of apoptosis. It was showed that TSA induced apoptosis in cells previously stimulated with the inducer of oxidative stress hydrogen peroxide (H20 2). Studies into the activation of caspase 3 in LPS- and TNF-a stimulated cells revealed that the combinatory effect of Dex or TA with TSA Significantly enhanced expression of the marker in all three cell lines. In resting cells, Dex, and TA, in the presence of TSA downregulated caspase 3 expression. These findings support the notion that glucocorticoid actions on apoptosis is mediated, at least in part, through an action on histone acetylation. Finally, histone acetylation was investigated in vivo in two rat models of inflammation and in human subjects with inflammatory bowel disease (IBD). The results showed an increase in histone H4 acetylation lysine specificity of acetylation on K8 and K12 in inflamed tissue and Peyer's patches in animal models and in IBD patients. Whereas H3 acetylation was not elevated to the same extent in tissue and was restricted to the mantle zone of Peyer's patches. In general, the present studies on histone acetylation and inflammation (in animal models and IBD patients) underlined the possibility of a general mechanism linking activation of the transcription factor NFKB with histone acetylation. The ultimate objective of this work is to aid in the understanding of the mechanisms of how deregulation of chromosome structure leads to progression of the disease state. This knowledge may aid in the development of new therapeutic approaches or improved glucocorticoids.
|
137 |
Efficacy of pharmacological agents on the remission induction and maintenance of Crohn's diseaseFarooq, Jeffrey 12 June 2019 (has links)
The two options for treatment of the inflammatory bowel disease Crohn’s Disease are surgery and pharmacotherapy. Pharmacotherapy with the goal of inducing and maintaining remission is the preferred treatment route, but the current medications are not entirely effective in achieving these goals. Approximately half of Crohn’s Disease patients will be required to have surgical bowel resection within 20 years of diagnosis, and many patients are at higher risk of adverse events such as cancer, either directly as a result of Crohn’s Disease or due to side-effects of the drugs used to treat the condition. Medical management of the disease is very complicated and there is a relative lack of uniformity in treatment. Different drugs used either in monotherapy, sequential therapy, or combination therapy produce differing levels of efficacy and different outcomes. This analysis provides an overview of the four major classes of drugs used in the treatment of Crohn’s Disease and a discussion of the overall efficacy of the different methods of treatment. While more studies need to be conducted into the differing outcomes of monotherapy, sequential therapy, and combination therapy, it appears as though any treatment involving the use of biologics such as tumor necrosis factor alpha (TNF-alpha) inhibitors results in improved outcomes relative to treatment styles that lack the use of biologics.
|
138 |
High dose interval vitamin D supplementation in pediatric patients with inflammatory bowel disease receiving RemicadeWells, Reeder M. 18 June 2019 (has links)
BACKGROUND: Patients suffering from inflammatory bowel disease (IBD) are at increased risk of vitamin D deficiency. Daily or weekly vitamin D supplementation has not proven to be effective in improving vitamin D status, and it is thought that this failure has been primarily due to a lack of compliance. Circulating vitamin D is crucial to bone growth and development in children and adolescents. However, more recent data has demonstrated that vitamin D also plays a significant role in the maintenance and regulation of the immune system.
OBJECTIVES: The primary aim of this study is to investigate the safety and efficacy of administering high dose oral vitamin D therapy in pediatric patients with IBD. We chose to study patients receiving Remicade, an immunosuppressive monoclonal antibody therapy administered intravenously, as the need for scheduled hospital-based infusions provides a unique opportunity to ensure compliance in our study population.
METHODS: We identified consecutive pediatric patients with IBD with a recent 25-hydroxyvitamin D (25OHD) level < 30ng/mL, maintained on Remicade, and with no history of kidney or liver disease for inclusion in the study from November 2017 and November 2018. Enrolled patients received one-year of open-label therapy. Vitamin D treatment doses were assigned by Remicade interval and patients received either 50,000 international units (IU) (every 4-5 weeks) or 100,000 IU (every 6-8 weeks) vitamin D3 orally at the time of their Remicade infusions. In addition to vitamin D levels, spot urine calcium to creatinine ratios, serum calcium, phosphorus, and blood urea nitrogen (BUN) levels, quality of life metrics, and surveys pertaining to dietary vitamin D intake and ultraviolet B (UVB) radiation exposure were collected throughout the study period.
RESULTS: Baseline vitamin D status in enrolled patients did not differ by gender, dosing group, diet, or diagnosis (Crohn disease or ulcerative colitis). Subjects reached steady-state serum 25OHD levels after three doses administered over a span of 4 to 8 months, our data demonstrated an increase in average 25OH vitamin D levels from 21.17 ng/mL to 28.19 ng/mL in the 50,000 IU and 23.00 ng/mL to 33.18 ng/mL in the 100,000 IU dose groups, respectively. The improvement in vitamin D status did not correlate with changes in quality of life or disease activity. The response to vitamin D therapy was independent of diet, sun exposure, race, gender, diagnosis, or season of enrollment. There were no adverse events, including changes in urine calcium to creatinine excretion or serum BUN and creatinine values. Several patients manifest a small decrease in serum phosphorus during the initial phase of the study. However, these changes were transient and no subjects exhibited clinical signs or symptoms of hypophosphatemia.
CONCLUSION: High dose, interval vitamin D supplementation achieved steady-state 25OHD levels of 30 ng/mL or greater, with no signs of toxicity in patients enrolled in this pilot study. These data suggest that high-dose interval therapy may be a feasible treatment option that bypasses limitations related to difficulties with patient compliance. Further studies are necessary to determine optimal dosage regimens and to assess endpoints related to immune function and improvements to gastrointestinal health.
|
139 |
Efeito da amitriptilina em um modelo murino de colite / Effect of amitriptyline in a murine model of colitisNamazu, Lilian Bernadete 02 April 2015 (has links)
Doenças inflamatórias intestinais (DII) em humanos são reações crônicas de etiologia complexa. Trata-se de uma reação imunológica exacerbada e depende da microbiota. O sistema nervoso interage com a imunidade do intestino de um modo bidirecional. Relatos clínicos e poucos achados experimentais apontam para uma ligação entre transtornos depressivos e doenças inflamatórias intestinais, sugerindo interação neuroimunológica na patogenia deste processo. Ainda, o tratamento de Doenças inflamatórias intestinais (DIIDoença de Crohn e Colite Ulcerativa) com antidepressivos em modelos murino de colite têm sugerido bons resultados na redução da inflamação. O mecanismo da inflamação na DII e a participação do sistema nervoso ou da modulação de tal processo pelo emprego de antidepressivos ainda não está totalmente elucidado. Este estudo teve como objetivo estudar o efeito do antidepressivo amitriptilina em um modelo murino de colite. A colite foi induzida em camundongos C57BL/6 por Dextrano Sulfato de Sódio (DSS) e a amitriptilina (AMT) foi administrada por via oral, em regime profilático ou terapêutico. Avaliamos a dose de AMT no teste de suspensão da cauda (TSC), o acúmulo de neutrófilos pela atividade de mieloperoxidase (MPO), burst oxidativo, curva de sobrevida, histopatologia do intestino, atividade da doença por sintomas clínicos, a depleção de muco intestinal, citocinas inflamatórias no cólon e no soro, fenotipagem de linfócitos T CD4+, T CD8+, e monócitos CD14+,. Resultados: A dose de AMT (200 μg/ml) e os regimes de tratamento utilizados aqui foram capazes de impedir ou diminuir a histopatologia da colite, os sinais clínicos (ganho de peso (%), comprimento e peso do cólon) e a mortalidade dos animais no modelo terapêutico do grupo inflamado e tratado com AMT. A atividade de MPO, níveis circulantes de IL- 1 β, IL- 6 e TNF- α foram reduzidas nos dois protocolos experimentais (profilático e terapêutico). Conclusões: Este estudo incluiu um período de tratamento prolongado, visto que os antidepressivos são conhecidos por serem eficazes em seres humanos depois de várias semanas a meses de prescrição, e confirmou a eficiência da via de administração oral, uma vez que os antidepressivos são geralmente administrados por via oral a seres humanos. Este regime de tratamento melhorou o potencial anti-inflamatório de AMT na redução DSS-colite em camundongos, com base nos parâmetros estudados / Inflammatory bowel disease (IBD) in humans is a complex etiology of chronic reactions. It is an exacerbated immune reaction and depends on the microflora. The nervous system interacts with the intestinal immunity of a bidirectional fashion. Clinical reports and few experimental findings point to a link between depressive disorders and inflammatory bowel disease, suggesting neuroimmunological interaction in the pathogenesis of this process. Also, treatment of inflammatory bowel diseases (Crohn\'s disease DII- and Ulcerative Colitis) with antidepressants in murine models of colitis have pointed to positive results in reducing inflammation. The mechanism of inflammation in IBD and the involvement of the nervous system or modulation of this process by the use of antidepressants is not yet fully elucidated. This study aimed to study the effect of amitriptyline in a murine model of colitis. Colitis was induced in C57BL / 6 mice by Dextran Sodium Sulfate (DSS) and amitriptyline (AMT) were orally administered in a prophylactic or therapeutic regimen. We evaluated the AMT dose in the tail suspension test (TST), the accumulation of neutrophils by myeloperoxidase activity (MPO), oxidative burst, survival curve, bowel histopathology, disease activity by clinical symptoms, depletion of intestinal mucus, colon and inflammatory cytokines in the serum phenotype of CD4+ T lymphocytes, CD8+ and CD14+ monocytes. Results: The dose of AMT (200 μg / ml) and treatment regimens used herein are able to prevent or decrease the pathology of colitis, clinical signs (weight gain (%), colon weight and length) and mortality animals in the therapeutic model inflamed group and treated with AMT. MPO activity, circulating levels of IL- 1 β, IL- 6 and TNF- α were reduced in both experimental protocols (prophylactic and therapeutic). Conclusions: This study included a prolonged period of treatment, as antidepressants are known to be effective in humans after several weeks or months of limitation, and confirmed the effectiveness of oral administration route, since antidepressants are generally administered orally to humans. This treatment scheme has improved potential anti-inflammatory AMT in reducing DSS colitis in mice based on the study parameters
|
140 |
Aconselhamento nutricional em idosos com constipação intestinal funcional: efeitos de ensaio clínico aleatorizado / Elderly's nutritional counseling with functional bowel constipation: causes of randomized clinic trialSalgueiro, Marcia Maria Hernandes de Abreu de Oliveira 21 February 2008 (has links)
Introdução: Os idosos representam um segmento demográfico crescente tanto nos países desenvolvidos como nos em desenvolvimento. A constipação intestinal é um sintoma relatado por 24 a 40% desses indivíduos, afetando 26% dos homens e 34% das mulheres. O consumo de uma dieta rica em fibras alimentares e líquidos ajuda na diminuição das queixas relacionadas à constipação intestinal funcional. Os idosos necessitam de atenção especial com intervenções dietéticas diferenciadas por meio de ações educativas específicas. Objetivo: Analisar os efeitos do aconselhamento nutricional centrado no cliente, em idosos com constipação intestinal funcional matriculados em ambulatório geriátrico. Métodos: O estudo foi experimental do tipo ensaio clínico aleatorizado realizado entre abril de 2002 e novembro de 2003. Os idosos foram alocados em grupo intervenção (n=19) e controle (n=21) e os dois grupos participaram de sete consultas mensais. O aconselhamento nutricional centrado no cliente foi o modelo educativo adotado nas consultas com o grupo intervenção. Esse modelo considera a educação como o processo de ensino, treinamento e facilitação, que permite a troca de informações entre o educador e o educando, por meio de uma linguagem entendível, dentro de um ambiente que conduz ao aprendizado. As variáveis analisadas foram: Índice de Massa Corporal (IMC), prática de atividade física, consumo alimentar (energia, carboidratos, lipídios, grupo das frutas, das leguminosas, ingestão de líquidos, grupo dos cereais, consumo de fibras alimentares), uso de medicamentos total e laxante e as queixas que caracterizam a constipação intestinal funcional. O consumo alimentar foi avaliado pelo recordatório de 24 horas em medidas caseiras e a atividade física pelo Questionário de Baecke. Os dados foram analisados por meio da Análise de Variância de Medidas Repetidas (paramétrica ou não paramétrica) e método de Bonferroni. O nível de significância adotado para os testes foi de 5%. Resultados: Os idosos mais jovens do grupo controle eram mais pesados que os mais velhos desde o início do acompanhamento (p=0,001) e os dois grupos não alteraram a prática de atividade física. O grupo intervenção aumentou o consumo de líquidos a partir da quarta consulta até o final do seguimento quando comparado à entrevista inicial (p=0,031) e, no que se refere à ingestão de leguminosas, observou-se aumento no consumo na quarta (p=0,028) e sexta (p=0,042) consultas na comparação intergrupos. Em relação ao uso de medicamentos total, tanto o grupo controle quanto o grupo intervenção não modificaram seu consumo (p=0,650), por outro lado, o grupo controle consumiu mais laxantes durante o acompanhamento quando comparado ao grupo intervenção (p=0,018). Os dois grupos apresentaram redução das queixas que caracterizam a constipação intestinal funcional durante o seguimento. Conclusões: Os resultados desse estudo indicam que o aconselhamento centrado no cliente é eficaz como uma abordagem educativa para a mudança de comportamento alimentar e conseqüente diminuição das queixas intestinais que caracterizam a constipação intestinal funcional. / Introduction: The elderly represent a growing demographic line not only in the developed countries but also the ones in developing. The bowel constipation is a related symptom for 24 to 40% of those persons, affecting 26% men e 34% women. The consumption of diet full in dietary fibers and liquids helps on decreasing of claims related to functional intestinal constipation. The elderly need to a special attention with diversified dietetics intervention through specific educated actions. Objective: Analyze the effects of client-centered nutritional counseling, in elderly with functional bowel constipation enrolled in geriatric ambulatory. Methods: The studying was experimental as a randomized clinic trial carried out between April 2002 and November 2003. Elderly were assigned in intervention group (n=19) and control (n=21) and both groups participated of seven consults, one per month. The client-centered nutritional counseling was the educating model adopted in consults with the intervention group. That model takes into account the education as the process of teaching, training and make it easy, that allows the changing of information between the educator and the student through understanding language inside of a place that lead to learning. The variables analyzed were: Body Mass Index (BMI), practice of physical activity, food intake (energy, carbohydrate, lipids, group of fruits, group of leguminous, ingestion of liquids, group of cereals, intake of dietary fibers), using of total drugs and laxatives and the claims that characterizes the functional bowel constipation. The food intake was evaluated with 24 hours recall on household measures and the physical activity by Baecke Questionnaire. The data were examined critically through Analyses of Variance With Repeated Measures (parametric and non-parametric) and Bonferroni's method. The significance level adopted to the tests was 5%. Results: The youngest elderly of control group were heavier than the oldest since the beginning of accompanying (p=0,001) and both group didn't change the practicing of physical activity. The intervention group increased the consumption of liquids since of fourth consult up the ending of segment when compared with initial interview (p=0,031) and, in what refers to ingestion of leguminous, it was observed an increasing in consumption in forth (p=0,028) and sixth (p=0,042) consults in the comparing between the groups. Relating the using of total drugs, not only the control group but also intervention group didn't change their consumption (p=0,650), on the other hand, the control group consumed more laxatives during the accompanying when compared to intervention group (p=0,018). Both groups presented reduction of claims that characteristic the functional bowel constipation during the segment. Conclusions: The results of that studying indicate that the client-centered counseling is efficient as an educative approach to the changing of alimentary behavior and consequent reduction of intestinal claims that characterize the functional bowel constipation.
|
Page generated in 0.0289 seconds